[1]罗 薇,韩 勇,王莉萍,等.西地兰联合贝那普利对老年冠心病心力衰竭患者心功能及金属蛋白酶组织抑制因子-4、游离脂肪酸表达的影响[J].陕西医学杂志,2021,50(2):216-220.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.023]
　LUO Wei,HAN Yong,WANG Liping,et al.Effects of cedilan and benazepril on cardiac function and expression of TIMP-4 and FFA in elderly patients with coronary heart disease and heart failure[J].,2021,50(2):216-220.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.023]
点击复制

西地兰联合贝那普利对老年冠心病心力衰竭患者心功能及金属蛋白酶组织抑制因子-4、游离脂肪酸表达的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年2期
页码:
216-220
栏目:
药物与临床
出版日期:
2021-02-05

文章信息/Info

Title:
Effects of cedilan and benazepril on cardiac function and expression of TIMP-4 and FFA in elderly patients with coronary heart disease and heart failure
作者:
罗 薇; 韩 勇; 王莉萍; 李渊博; 张园园
(西安市红会医院心内科,陕西 西安 710054)
Author(s):
LUO Wei; HAN Yong; WANG Liping; LI Yuanbo; ZHANG Yuanyuan
(Department of Cardiology,Xi'an Honghui Hospital,Xi'an 710054,China)
关键词:
西地兰;  贝那普利;  冠心病;  心力衰竭;  心功能;  金属蛋白酶组织抑制因子-4;  游离脂肪酸
Keywords:
Cedilan;  Benazepril;  Coronary heart disease;  Heart failure;  Heart function;  Tissue inhibitor of metalloproteinase-4;  Free fatty acid
分类号:
R 541.61
DOI:
DOI:10.3969/j.issn.1000-7377.2021.02.023
文献标志码:
A
摘要:
目的:探讨西地兰联合贝那普利对老年冠心病心力衰竭患者心功能及金属蛋白酶组织抑制因子-4(TIMP-4)、游离脂肪酸(FFA)表达的影响。方法:选取老年冠心病心力衰竭患者106例,根据治疗方案不同分为对照A组(n=35)、对照B组(n=35)、联合组(n=36)。三组入院后均采取常规干预,在此基础上对照A组采取西地兰,对照B组采取贝那普利,联合组采取西地兰及贝那普利,均治疗4周。统计三组临床疗效、治疗前及治疗4周后心功能、心室重构指标水平、TIMP-4及FFA水平、血管内皮功能指标[血管舒张功能(FMD)、内皮祖细胞(EPCs)]、不良反应。结果:联合组总有效率(94.44%)高于对照A组(74.29%)及对照B组(74.29%)(均P<0.05); 治疗后三组左心室射血分数(LVEF)、心脏指数(CI)、每搏量(SV)、二尖瓣E峰峰值血流速度/A峰峰值血流速度(E/A)较治疗前增高,且联合组高于对照A组、对照B组(均P<0.05); 治疗后三组左室收缩末期容积(LVESV)、左室舒张末期容积(LVEDV)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)较治疗前降低,且联合组低于对照A组、对照B组(均P<0.05); 治疗后三组血清TIMP-4水平较治疗前增高,FFA水平较治疗前降低,且联合组血清TIMP-4水平高于对照A组、对照B组,FFA水平低于对照A组、对照B组(均P<0.05); 治疗后三组FMD、EPCs较治疗前增高,且联合组高于对照A组、对照B组(均P<0.05); 联合组不良反应发生率与对照A组、对照B组间比较无统计学差异(均P>0.05)。结论:联合采取西地兰及贝那普利治疗冠心病心力衰竭的老年患者,可有效改善其心功能,抑制心室重塑,提高疾病治疗效果,并能调节血清TIMP-4及FFA水平,改善血管内皮功能,且具有一定安全性。
Abstract:
Objective:To investigate the effects of cedilan and benazepril on cardiac function and expression of tissue inhibitor of metalloproteinase-4(TIMP-4)and free fatty acids(FFA)in elderly patients with coronary heart disease and heart failure.Methods:106 elderly patients with coronary heart disease and heart failure were selected and divided into control group A(n=35),control group B(n=35),and combined group(n=36).All three groups received routine intervention after admission.On this basis,the control group A was treated with cedilan,the control group B was treated with benazepril,and the combined group was treated with cedilan and benazepril,all of which were treated for 4 weeks.The clinical efficacy,cardiac function,ventricular remodeling index level,TIMP-4 and FFA levels,vascular endothelial function indexes [vasodilation function(FMD),endothelial progenitor cells(EPCs)],and adverse reactions of the three groups before and 4 weeks after treatment were analyzed.Results:The total effective rate of the combined group(94.44%)was higher than that of the control group A(74.29%)and the control group B(74.29%)(all P<0.05).After treatment,the LVEF,CI,SV,and E/A of the three groups were higher than those before treatment,and the combined group was higher than another two groups(all P<0.05).After treatment,LVESV,LVEDV,LVEDD,and LVESD in the three groups were lower than those before treatment,and the combined group was lower than another two groups(all P<0.05).After treatment,the serum TIMP-4 levels in the three groups were higher than those before treatment,and the FFA levels were lower than those before treatment.The serum TIMP-4 level in the combined group was higher than that in another two groups,and the FFA level was lower than that in another two groups(all P<0.05).After treatment,the FMD and EPCs of the three groups were higher than those before treatment,and the combined group was higher than another two groups(all P<0.05).The incidence of adverse reactions in the combination group was not significantly different from that in another two groups(all P>0.05).Conclusion:The combined use of cedilan and benazepril in the treatment of elderly patients with coronary heart disease and heart failure can effectively improve their heart function,inhibit ventricular remodeling,improve the effect of disease treatment,and can regulate serum TIMP-4 and FFA levels,improve vascular endothelial function,and has a certain safety.

参考文献/References:

[1] 刘 鹏,高学良,原建华,等.心脉隆治疗冠心病心力衰竭的临床疗效及对血浆高敏C反应蛋白和N末端B型脑钠肽前体的影响[J].中华老年医学杂志,2017,36(5):502-505.
[2] 方凌燕,李日行,凌 云,等.增强型体外反搏联合曲美他嗪对冠心病慢性心力衰竭病人心功能的影响[J].中西医结合心脑血管病杂志,2019,17(15):2323-2325.
[3] 吴亚华,沈 华.西地兰在心力衰竭时的干预效果分析[J].中国生化药物杂志,2017,37(8):172-173.
[4] Held C,White HD,Stewart R,et al.Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease:Experiences from the stability(stabilization of atherosclerotic plaque by initiation of darapladib therapy)trial[J].J Am Heart Assoc,2017,6(10):5077.
[5] 姜 明,乔 锐.丹参酮ⅡA磺酸钠注射液联合贝那普利治疗冠心病心力衰竭的临床疗效及其对心功能、血液流变学的影响[J].实用心脑肺血管病杂志,2018,26(10):104-107.
[6] 刘永建,齐洪娜,李 佳,等.贝那普利联合曲美他嗪对老年冠心病并发慢性心力衰竭患者的炎性细胞因子及心功能的影响[J].广西医学,2016,38(5):644-647.
[7] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性心力衰竭诊断和治疗指南[J].中华心血管病杂志,2010,8(3):605-615.
[8] Peng Y,Ou BQ,Li HH,et al.Synergistic effect of atorvastatin and folic acid on cardiac function and ventricular remodeling in chronic heart failure patients with hyperhomocysteinemia[J].Med Sci Monit,2018,24(4):3744-3751.
[9] 刘廷怡,刘 瑶,王安伟.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效[J].解放军预防医学杂志,2018,36(6):713-716.
[10] 陈 颖,冯亚招.多巴胺联合西地兰治疗小儿肺炎合并心力衰竭临床疗效分析[J].海南医学,2016,27(12):2007-2009.
[11] 李宗卫.西地兰联合美托洛尔治疗急性左心衰合并房颤临床效果分析[J].中西医结合心脑血管病杂志,2017,15(15):1869-1871.
[12] 尚晨黧,高 珊,王丽超.米力农联合西地兰治疗慢性心力衰竭的疗效观察及安全性分析[J].现代诊断与治疗,2018,29(14):2217-2219.
[13] 姚亚军,陈维明,施益忠,等.米力农联合西地兰治疗慢性心力衰竭的疗效评估[J].安徽医药,2017,21(10):1900-1902.
[14] King JN,Hirakawa A,Sonobe J.Evaluation of a fixed dose combination of benazepril and pimobendan in dogs with congestive heart failure:A randomized non-inferiority clinical trial[J].J Vet Sci,2018,19(1):117-128.
[15] 李颜兵,惠芳玲,杜海蓉.贝那普利并曲美他嗪对冠心病并心衰患者血清FSTL1、PAF及血管内皮功能的影响[J].心血管康复医学杂志,2017,26(5):533-538.
[16] 昝文明,王鑫燕,昝占全.瑞舒伐他汀联合富马酸比索洛尔对冠心病慢性心力衰竭患者症状改善及血清金属蛋白酶组织抑制因子4和游离脂肪酸水平的影响[J].中国慢性病预防与控制,2019,27(4):265-267,271.
[17] 魏红随,王 刚,刘兴芝.慢性心力衰竭患者血浆TIMP、sES及FFA动态变化及预后判断[J].心脑血管病防治,2017,17(4):256-259.

备注/Memo

备注/Memo:
基金项目:陕西省自然科学基金资助一般面上项目(2020JM-692)
更新日期/Last Update: 2021-01-28